Assignee
HORIZON THERAPEUTICS USA INC
US·10 granted patents·5 pending applications·27 citations·filing 2017–2025
Top patents by PatentIndex Score
15 records- 0198US11781119B2Variant forms of urate oxidase and use thereofHORIZON THERAPEUTICS USA INC·Filed 2022·Granted Oct 10, 2023·5 cites·23 claims
- 0298US11345899B2Variant forms of urate oxidase and use thereofHORIZON THERAPEUTICS USA INC·Filed 2020·Granted May 31, 2022·10 cites·20 claims
- 0396US11639927B2Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapyHORIZON THERAPEUTICS USA INC·Filed 2020·Granted May 2, 2023·7 cites·9 claims
- 0496US11598767B2Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapyHORIZON THERAPEUTICS USA INC·Filed 2022·Granted Mar 7, 2023·5 cites·4 claims
- 0594US12560596B2Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapyHORIZON THERAPEUTICS USA INC·Filed 2025·Granted Feb 24, 2026·0 cites·27 claims
- 0691US2025231181A1Methods and kits for predicting infusion reaction risk and antibody mediated loss of response by monitoring serum uric acid during pegylated uricase therapyHORIZON THERAPEUTICS USA INC·Filed 2024·Application pending·0 cites
- 0790US12188927B2Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapyHORIZON THERAPEUTICS USA INC·Filed 2024·Granted Jan 7, 2025·0 cites·17 claims
- 0885US11982670B2Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapyHORIZON THERAPEUTICS USA INC·Filed 2023·Granted May 14, 2024·0 cites·9 claims
- 0970US2024026312A1Purification of proteins with cationic surfactantHORIZON THERAPEUTICS USA INC·Filed 2023·Application pending·0 cites
- 1069US2024033331A1Reducing immunogenicity to pegloticaseHORIZON THERAPEUTICS USA INC·Filed 2023·Application pending·0 cites
- 1167US2025009849A1Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)HORIZON THERAPEUTICS USA INC·Filed 2024·Application pending·0 cites
- 1266US12465631B2Reducing immunogenicity to pegloticaseHORIZON THERAPEUTICS USA INC·Filed 2022·Granted Nov 11, 2025·0 cites·18 claims
- 1356US12121566B2Methods for treating goutHORIZON THERAPEUTICS USA INC·Filed 2020·Granted Oct 22, 2024·0 cites·16 claims
- 1454US2023301999A1Methods of treating goutHORIZON THERAPEUTICS USA INC·Filed 2021·Application pending·0 cites
- 1539US12496331B2Combination therapies of prednisone and uricase molecules and uses thereofHORIZON THERAPEUTICS USA INC·Filed 2017·Granted Dec 16, 2025·0 cites·7 claims
Join the waitlist — get patent alerts
Get an alert when HORIZON THERAPEUTICS USA INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →